{"id":48106,"date":"2025-11-14T16:08:00","date_gmt":"2025-11-14T08:08:00","guid":{"rendered":"https:\/\/flcube.com\/?p=48106"},"modified":"2025-11-14T16:08:02","modified_gmt":"2025-11-14T08:08:02","slug":"adagene-licenses-safebody-platform-to-third-arc-bio-for-masked-cd3-t%e2%80%91cell-engagers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48106","title":{"rendered":"Adagene Licenses SAFEbody Platform to Third\u202fArc Bio for Masked CD3 T\u2011Cell Engagers"},"content":{"rendered":"\n

Adagene Inc.<\/strong> (NASDAQ: ADAG<\/a>) and Third Arc Bio, Inc.<\/strong> announced today that they have signed a global licensing agreement<\/strong> under which Third\u202fArc Bio will employ Adagene\u2019s proprietary SAFEbody\u2122 safety antibody technology<\/strong> to create masked CD3 T\u2011cell engagers (TCEs)<\/strong> directed at selected tumor\u2011associated antigens (TAAs).<\/p>\n\n\n\n

Deal Terms<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Scope<\/strong><\/td>Third\u202fArc Bio receives worldwide rights to research, develop and commercialize two candidate masked CD3 TCEs<\/strong>.<\/td><\/tr>
Up\u2011front cash<\/strong><\/td>USD\u202f5\u202fmillion<\/strong> payable to Adagene upon signing.<\/td><\/tr>
Potential milestones<\/strong><\/td>Up to USD\u202f840\u202fmillion<\/strong> in research, development and commercial milestones.<\/td><\/tr>
Royalties<\/strong><\/td>Adagene to earn a royalty on net sales of the licensed TCEs (percentage disclosed in the definitive agreement).<\/td><\/tr>
Territorial carve\u2011outs<\/strong><\/td>Adagene retains a non\u2011exclusive option<\/strong> to develop and commercialize the two candidates in Greater China, Singapore and South Korea<\/strong>.<\/td><\/tr>
Technology<\/strong><\/td>SAFEbody\u2122 platform \u2013 a \u201cmask\u2011and\u2011unmask\u201d antibody architecture that shields CD3 binding until the molecule reaches the tumor micro\u2011environment, improving safety and therapeutic index.<\/td><\/tr>
Target indication<\/strong><\/td>Early\u2011stage oncology programs focusing on solid\u2011tumor TAAs (specific antigens confidential).<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n
    \n
  1. Accelerated pipeline for Third\u202fArc Bio<\/strong> \u2013 The SAFEbody platform provides a proven safety switch, allowing Third\u202fArc Bio to advance masked CD3 TCEs with reduced cytokine\u2011release\u2011syndrome risk.<\/li>\n\n\n\n
  2. Revenue diversification for Adagene<\/strong> \u2013 The deal adds a high\u2011up\u2011front cash infusion<\/strong> and a sizable milestone upside<\/strong>, while preserving a foothold in the fast\u2011growing Asian markets.<\/li>\n\n\n\n
  3. Market opportunity<\/strong> \u2013 The global T\u2011cell engager market is projected to exceed USD\u202f12\u202fbillion by 2030<\/strong>; masked CD3 TCEs are positioned to capture a share of the solid\u2011tumor segment<\/strong>, which currently lags behind hematologic indications.<\/li>\n<\/ol>\n\n\n\n

    Financial Impact<\/h2>\n\n\n\n